Sustained infections under substitution of IgG (Immunoglobuline G)

Sustained infections under substitution of IgG (Immunoglobuline G) - SINUS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00010561

Enrollment

250

Registered

2016-05-25

Start date

2016-06-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D83.0

Interventions

Group 1: Patients with CVID (common variable immunodeficiency) complete one-time a questionnaire in terms of their current health situation focusing on infect susceptibility in spite of immunoglobulin

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: diagnosis of PID (primary immunodeficiency) with antibody deficiency, male and female patients, 18 years, understanding of German language, informed consent available

Exclusion criteria

Exclusion criteria: no

Design outcomes

Primary

Measure	Time frame
Prevalence of persistent infection suceptibility despite immunoglobuline substitution therapy	—

Secondary

Measure	Time frame
•Willingness of patients with persistent infection susceptibility in spite of standard immunoglobulin substitution therapy (intravenous or subcutanous) to receive an alternative intravenous immunoglobuline supportive therapy with one- or two-weekly application •Association of persistent infection susceptibility in spite of immunoglobulin substitution therapy with reduced IgM and IgA serum level	—

Measure

Time frame

•Willingness of patients with persistent infection susceptibility in spite of standard immunoglobulin substitution therapy (intravenous or subcutanous) to receive an alternative intravenous immunoglobuline supportive therapy with one- or two-weekly application •Association of persistent infection susceptibility in spite of immunoglobulin substitution therapy with reduced IgM and IgA serum level

—

Countries

Germany

Contacts

Public ContactKlaus Warnatz

Universitätsklinikum FreiburgCentrum für Chronische Immundefizienz (CCI)

klaus.warnatz@uniklinik-freiburg.de0761 270 77640

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026